Trocando Idéias XV

24 de junho de 2010

Outros Impactos da Vacinação Contra o HPV
Mudanças no Rastreio

Flávia de Miranda Corrêa
Divisão de Apoio à Rede de Atenção Oncológica
INCA

Futurologia



O rastreio deve continuar na população vacinada?

SIM

- Apenas 2 subtipos oncogênicos: 70% dos casos de câncer

Figure 25: Ten most frequent HPV types among women with and without cervical lesions in Brazil compared to South America and the World



WHO/ICO Information Centre on HPV and Cervical Cancer *(HPV Information Centre). Human Papillomavirus and Related Cancers in Brazil. Summary Report 2010.* Disponível em **www.who.int/hpvcentre** (acessado em 21/jun/2010)

Lacunas de conhecimento

Garnett GP. *Modelling the impact of HPV vaccines on cervical cancer and screening programmes.* ***Vaccine 2006****; 24 Suppl 3:S3/178-86.*

Table 2. Comparison of the efficacy of the quadrivalent human papillomavirus (HPV) vaccine (Gardasil) and the bivalent HPV vaccine (Cervarix)

	Efficacy against indicated type, % (CI[a])				
Vaccine	HPV-31	HPV-33	HPV-45	HPV-52	HPV-58
Gardasil[b]	46.2 (15.3 to 66.4)	28.7 (−45.1 to 65.8)	7.8 (−67.0 to 49.3)	18.4 (−20.6 to 45.0)	5.5 (−54.3 to 42.2)
Cervarix[c]	36.1 (0.5 to 59.5)	36.5 (−9.9 to 64.0)	59.9 (2.6 to 85.2)	31.6 (3.5 to 51.9)	−31.4 (−132.1 to 24.7)



Herrero R. *Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.* ***J Infect Dis. 2009*** *;199(7):919-22.*



WHO/ICO Information Centre on HPV and Cervical Cancer *(HPV Information Centre). Human Papillomavirus and Related Cancers in Brazil. Summary Report 2010.* Disponível em **www.who.int/hpvcentre** (acessado em 21/jun/2010)

Qual será o impacto no rastreio?

Teste	Lesão presente	Lesão ausente	Total
Positivo	VP	FP	T+
Negativo	FN	VN	T-
Total	L+	L-	N

S = VP / VP+FN **E = VN / VN+FP** **VPP = VP / VP+FP** **VPN = VN /VN+FN**

Qual será o impacto no número de FN?



Possibilidade de aumento no intervalo do rastreio

*Myers E et al. The current and future role of screening in the era of HPV vaccination. **Gynecol Oncol 2008**; 109(2 Suppl):S31-9.*

Qual será o impacto no número de FP?



Possibilidade de aumento no sobrediagnóstico e sobretratamento

Myers E et al. The current and future role of HPV vaccination. Gynecol Oncol 2008; 109(2 Suppl):S31-9.

Qual será o impacto nos VP?



***Franco E** et al. Issues in planning cervical cancer screening in the era of HPV vaccination. **Vaccine 2006**;24 Suppl 3:S3/171-7.*

Impacto qualitativo na citologia

Após vacina

10% → 1%

- Diminuição S/VPN, aumento FN:

- monotonia de casos negativos
- leitura menos meticulosa
- < identificação de anormalidades

- Diminuição E/VPP e aumento FP:

- medo de perder alteração relevante
- supervalorização de casos negativos

Após DNA-HPV+

1% → 50%

- Aumento S/VPN, diminuição FN:

- estímulo por casos positivos
- leitura mais cuidadosa

- Aumento E/VPP, diminuição FP:

- maior treinamento
- equilíbrio entre casos + e –

Franco E et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009;40(6):478-85.

EXPECTED IMPACT OF HPV VACCINATION ON DISEASE PREVALENCE AND ON THE SCREENING PERFORMANCE OF PAP CYTOLOGY

Prevalence of any abnormality in a Pap smear

Franco E. *HPV Today* ***2008****;15:1-4.*
Disponível em **www.hpvtoday.com**
(acessado em 21/jun/2010)



ALGORITHMIC EVOLUTION of CERVICAL SCREENING OVER TIME

Ferenczy A. HPV Today 2008. Disponível em **www.hpvtoday.com** (acessado em 21/jun/2010)

PROPHYLACTIC HPV VACCINATION

Traditional	Current	Proposed	Ultimate
Pap cytology	*Pap and* HR-HPV DNA *testing* (HC-2) (*simultaneously*)	HR-HPV DNA *testing* - *Pap only for* HR-HPV(+)	HR-HPV DNA *testing* - *Genotyping in* HR-HPV(+)

PAST and PROSPECTS of the PAP CYTOLOGY for SCREENING